What is Bio Essence's earnings per share (EPS)?

Bio Essence (BIOE) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a 166.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bio Essence Financials

BIOE

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows Bio Essence (BIOE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Cash-Backed

1.75x

For every $1 of reported earnings, Bio Essence generates $1.75 in operating cash flow ($1.6M OCF vs $896K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

411.7x

Bio Essence earns $411.7 in operating income for every $1 of interest expense ($900K vs $2K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.9M

YoY+485.8%

5Y CAGR+14.6%

Bio Essence generated $1.9M in revenue in fiscal year 2025. This represents an increase of 485.8% from the prior year.

EBITDA

$900K

YoY+296.3%

Bio Essence's EBITDA was $900K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 296.3% from the prior year.

Net Income

$896K

YoY+168.5%

Bio Essence reported $896K in net income in fiscal year 2025. This represents an increase of 168.5% from the prior year.

EPS (Diluted)

$0.02

YoY+166.7%

Bio Essence earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 166.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

38M

YoY+0.0%

5Y CAGR+2.9%

Bio Essence had 38M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

75.3%

YoY+8.3pp

5Y CAGR+51.6pp

Bio Essence's gross margin was 75.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 8.3 percentage points from the prior year.

Operating Margin

47.4%

YoY+189.3pp

5Y CAGR+134.3pp

Bio Essence's operating margin was 47.4% in fiscal year 2025, reflecting core business profitability. This is up 189.3 percentage points from the prior year.

Net Margin

47.2%

YoY+451.2pp

5Y CAGR+109.4pp

Bio Essence's net profit margin was 47.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 451.2 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

BIOE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.9M+485.8%	$324K-41.3%	$552K-11.3%	$622K-30.0%	$888K-7.4%	$959K
Cost of Revenue	$21K-80.8%	$107K-61.0%	$274K-6.5%	$293K+219.6%	$92K-87.5%	$731K
Gross Profit	$1.4M+558.0%	$217K-21.8%	$277K-15.5%	$328K+10.1%	$298K+31.3%	$227K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$498K-26.4%	$677K+95.8%	$346K-54.7%	$763K-29.1%	$1.1M+18.6%	$908K
Operating Income	$900K+295.9%	-$459K-32.9%	-$346K+32.4%	-$511K+40.4%	-$858K-3.0%	-$833K
Interest Expense	$2K+1.5%	$2K-87.6%	$17K+22.7%	$14K-63.4%	$39K-8.0%	$42K
Income Tax	$8000.0%	$800-50.0%	$2K-36.0%	$3K-24.2%	$3K0.0%	$3K
Net Income	$896K+168.5%	-$1.3M-34.7%	-$972K-20.0%	-$810K-25.0%	-$648K-8.7%	-$596K
EPS (Diluted)	$0.02+166.7%	$-0.030.0%	$-0.03-50.0%	$-0.020.0%	$-0.02	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$137K-47.2%	$259K+1067.8%	$22K	N/A	$135K+223.0%	$42K	N/A	N/A
Cost of Revenue	$41K-54.6%	$90K+5551.4%	$2K	N/A	$54K+329.3%	$13K	N/A	N/A
Gross Profit	$96K-43.2%	$169K+719.1%	$21K	N/A	$81K+177.5%	$29K	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$81K-24.7%	$107K-52.3%	$225K	N/A	$227K+17.1%	$194K+27.9%	$152K	N/A
Operating Income	$14K-76.7%	$61K+129.9%	-$205K	N/A	-$146K+11.3%	-$165K-8.7%	-$152K	N/A
Interest Expense	$556+1.6%	$547+0.7%	$543	N/A	$536-0.6%	$539-0.6%	$542	N/A
Income Tax	N/A	$800	N/A	N/A	N/A	$800	N/A	N/A
Net Income	$13K-78.3%	$60K+129.1%	-$206K	N/A	-$1.2M-456.1%	-$216K-261.0%	$134K	N/A
EPS (Diluted)	$0.00	$0.00+100.0%	$-0.01	N/A	$-0.03-200.0%	$-0.01	$0.00	N/A

BIOE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$281K-89.8%	$2.8M+78.2%	$1.5M-8.9%	$1.7M-7.9%	$1.8M
Current Assets	N/A	$281K-6.4%	$300K+47.2%	$204K-22.2%	$262K-20.5%	$330K
Cash & Equivalents	N/A	$1K+1102.6%	$114-98.2%	$6K+1966.7%	$303-94.3%	$5K
Inventory	N/A	N/A	$143K-20.9%	$181K-14.9%	$213K-21.8%	$272K
Accounts Receivable	N/A	$5K-85.4%	$35K+526.8%	$6K-66.7%	$17K-62.7%	$45K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$3.3M-26.4%	$4.4M-7.7%	$4.8M+15.9%	$4.1M+13.8%	$3.6M
Current Liabilities	N/A	$2.8M+14.4%	$2.5M-31.1%	$3.6M+29.1%	$2.8M+45.4%	$1.9M
Long-Term Debt	N/A	$56K	N/A	N/A	N/A	N/A
Total Equity	N/A	-$3.0M-78.8%	-$1.7M+48.7%	-$3.2M-33.3%	-$2.4M-36.4%	-$1.8M
Retained Earnings	N/A	-$10.4M-14.3%	-$9.1M-11.9%	-$8.2M-11.0%	-$7.4M-9.6%	-$6.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$185K+63.8%	$113K-69.2%	$366K+30.1%	$281K-60.7%	$716K-65.8%	$2.1M-7.1%	$2.3M-18.3%	$2.8M
Current Assets	$184K+63.9%	$112K-69.2%	$365K+30.2%	$281K-60.8%	$716K-21.9%	$917K+2.2%	$897K+199.1%	$300K
Cash & Equivalents	$29K	N/A	N/A	$1K-95.4%	$30K+214.2%	$9K+41156.5%	$23-79.8%	$114
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$143K
Accounts Receivable	$5K0.0%	$5K-39.3%	$8K+59.9%	$5K-92.2%	$65K+729.8%	$8K	N/A	$35K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M+1.8%	$3.2M-8.8%	$3.5M+8.9%	$3.3M-11.1%	$3.7M-4.7%	$3.8M+1.5%	$3.8M-14.4%	$4.4M
Current Liabilities	$3.2M+5.2%	$3.1M-5.2%	$3.2M+15.6%	$2.8M-8.6%	$3.1M-1.4%	$3.1M+6.5%	$2.9M+19.1%	$2.5M
Long-Term Debt	$58K-0.5%	$58K+3.5%	$56K-0.6%	$56K-0.6%	$57K	N/A	N/A	N/A
Total Equity	-$3.1M+0.4%	-$3.1M+1.9%	-$3.2M-6.9%	-$3.0M-0.9%	-$2.9M-68.9%	-$1.7M-14.1%	-$1.5M+8.1%	-$1.7M
Retained Earnings	-$10.6M+0.1%	-$10.6M+0.6%	-$10.7M-2.0%	-$10.4M-0.3%	-$10.4M-13.0%	-$9.2M-2.4%	-$9.0M+1.5%	-$9.1M

BIOE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.6M+151.6%	$624K+160.8%	-$1.0M-45.8%	-$703K+45.7%	-$1.3M-76.6%	-$733K
Capital Expenditures	N/A	N/A	$4K-3.4%	$4K-96.9%	$119K+1522.5%	$7K
Free Cash Flow	N/A	N/A	-$1.0M-45.6%	-$707K+50.0%	-$1.4M-91.0%	-$740K
Investing Cash Flow	-$1140.0%	-$114+99.9%	-$91K-54.7%	-$59K+49.4%	-$117K-1485.8%	-$7K
Financing Cash Flow	-$1.6M-152.4%	-$622K-156.0%	$1.1M+44.6%	$768K-45.3%	$1.4M+92.8%	$729K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$187K+11.4%	$168K+743.7%	-$26K-106.2%	$423K+18.5%	$357K+2238.4%	$15K+108.9%	-$172K+15.9%	-$204K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$204K
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$88K
Financing Cash Flow	-$158K+5.7%	-$168K-779.4%	$25K+105.5%	-$452K-34.1%	-$337K-5700.1%	-$6K-103.4%	$172K-41.2%	$292K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BIOE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	75.3%+8.3pp	67.0%+16.7pp	50.3%-2.5pp	52.8%+19.2pp	33.6%+9.9pp	23.7%
Operating Margin	47.4%+189.3pp	-141.8%-79.2pp	-62.7%+19.6pp	-82.2%+14.3pp	-96.6%-9.7pp	-86.8%
Net Margin	47.2%+451.2pp	-404.0%-227.8pp	-176.2%-46.0pp	-130.3%-57.3pp	-72.9%-10.8pp	-62.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-465.7%-430.5pp	-35.2%+17.1pp	-52.3%-14.2pp	-38.1%-5.8pp	-32.3%
Current Ratio	N/A	0.10-0.0	0.12+0.1	0.06-0.0	0.10-0.1	0.17
Debt-to-Equity	N/A	-0.02+2.6	-2.66-1.2	-1.48+0.2	-1.70+0.3	-2.04
FCF Margin	N/A	N/A	-186.6%-72.9pp	-113.7%+45.5pp	-159.2%-82.0pp	-77.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	70.0%+4.9pp	65.1%-27.7pp	92.8%	N/A	60.1%-9.9pp	70.0%	N/A	N/A
Operating Margin	10.4%-13.2pp	23.6%+947.9pp	-924.3%	N/A	-108.7%+287.0pp	-395.8%	N/A	N/A
Net Margin	9.5%-13.6pp	23.1%+950.4pp	-927.3%	N/A	-890.6%-373.3pp	-517.3%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	7.0%-46.1pp	53.1%+109.4pp	-56.3%	N/A	-167.5%-157.2pp	-10.3%-16.2pp	5.9%	N/A
Current Ratio	0.06+0.0	0.04-0.1	0.11+0.0	0.10-0.1	0.23-0.1	0.29-0.0	0.31+0.2	0.12
Debt-to-Equity	-0.020.0	-0.020.0	-0.020.0	-0.020.0	-0.02+2.2	-2.20+0.3	-2.48+0.2	-2.66
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is Bio Essence's annual revenue?

Bio Essence (BIOE) reported $1.9M in total revenue for fiscal year 2025. This represents a 485.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bio Essence's revenue growing?

Bio Essence (BIOE) revenue grew by 485.8% year-over-year, from $324K to $1.9M in fiscal year 2025.

Is Bio Essence profitable?

Yes, Bio Essence (BIOE) reported a net income of $896K in fiscal year 2025, with a net profit margin of 47.2%.

What is Bio Essence's EBITDA?

Bio Essence (BIOE) had EBITDA of $900K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bio Essence's gross margin?

Bio Essence (BIOE) had a gross margin of 75.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bio Essence's operating margin?

Bio Essence (BIOE) had an operating margin of 47.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bio Essence's net profit margin?

Bio Essence (BIOE) had a net profit margin of 47.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bio Essence's operating cash flow?

Bio Essence (BIOE) generated $1.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How many shares does Bio Essence have outstanding?

Bio Essence (BIOE) had 38M shares outstanding as of fiscal year 2025.

Are Bio Essence's earnings high quality?

Bio Essence (BIOE) has an earnings quality ratio of 1.75x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bio Essence cover its interest payments?

Bio Essence (BIOE) has an interest coverage ratio of 411.7x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.